Description:
This study is to explore the markers in early prediction of the efficacy of pre-operative
pertuzumab plus trastuzumab (PH) combined with chemotherapy for early stage or locally
advanced human epidermal growth factor receptor-2 (HER-2) positive primary breast cancer.
Title
- Brief Title: Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer
- Official Title: Gene Expression Assays and 68 Ga-Affibody HER-2 Imaging PET in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Chinese Patients With HER2 Positive Breast Cancer
Clinical Trial IDs
- ORG STUDY ID:
SCHBCC-NO28
- NCT ID:
NCT04281641
Conditions
- HER2-positive Breast Cancer
Purpose
This study is to explore the markers in early prediction of the efficacy of pre-operative
pertuzumab plus trastuzumab (PH) combined with chemotherapy for early stage or locally
advanced human epidermal growth factor receptor-2 (HER-2) positive primary breast cancer.
Detailed Description
This study is to evaluate the correlation between early changes in multiple markers and
pathological complete response in breast and lyphm nodes (tpCR) in patients with
HER2-positive breast cancer receiving carboplatin, docetaxel and trastuzumab plus pertuzumab
(TCHP) pre-operatively. The markers would be examined by gene expression assays,
fluorodeoxyglucose positron emission tomography (18F-FDG-PET), 68 Ga-Affibody HER-2 Imaging
PET, and organoid drug sensitivity test. Approximately 94 patients were treated with PH-based
neoadjuvant therapy followed by surgery, and would complete 1 year of PH-based regimen in the
adjuvant setting. The primary endpoint is the percent change of SUVmax from baseline to Day
15 (after the first cycle of anti HER-2 targeting drug treatment) on FDG PET and HER-2
imagining PET in correlation with pathological complete response (pCR) in patients treated
with preoperative pertuzumab and trastuzumab. pCR was defined as no viable invasive cancer in
breast and axilla by local pathology review.
Trial Arms
Name | Type | Description | Interventions |
---|
TCHP | Experimental | Neoadjuvant Therapy (Cycles 1-7):
Cycle 1: Pertuzumab (840mg loading dose, 420mg maintenance dose) + Trastuzumab (8mg/kg loading dose, 6-mg/kg maintenance dose) Cycle 2-7: Pertuzumab (840mg loading dose, 420mg maintenance dose) + Trastuzumab (8mg/kg loading dose, 6-mg/kg maintenance dose) + followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w).
Adjuvant Therapy:patients would complete 1 year of PH-based regimen in the adjuvant setting.
Patients are assessed by [18F]Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and 68Ga-Affibody HER-2 Imaging PET. Besides, the changes of biomarkers would be examined by gene sequencing and organoid drug sensitivity test. | |
Eligibility Criteria
Inclusion Criteria:
1. Female or male, presenting for the first time with operable breast cancer, who had not
received any previous treatment for an invasive malignancy.
2. Primary tumor greater than (>) 2 cm in diameter.
3. Age ≥ 18 years and < 70 years.
4. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
(</=) 1.
5. Baseline left ventricular ejection fraction (LVEF) greater than or equal to (>/=) 55%
6. Availability of tumor tissue specimen after surgery.
7. Participants agree to undergo a core needle biopsy for genomic testing and organoid
drug sensitivity assay.
8. Histologically proven diagnosis of breast cancer.
9. Patients have HER2-positive disease. HER2-positive disease was defined as follows:
disease which overexpresses HER-2 by immunohistochemistry (IHC) 3+ and/or has HER2
amplification according to fluorescence in situ hybridization (FISH).
10. Had hormonal receptors (ER and PgR) assessed.
11. Signed informed consent.
12. Able to comply with the protocol.
Exclusion Criteria:
1. Metastatic disease (Stage IV) or bilateral breast cancer.
2. Any previous systemic therapy (including chemotherapy, immunotherapy, HER2 targeted
agents, and antitumor vaccines) for cancer, or radiation therapy for cancer.
3. Prior breast or non-breast malignancy within 5 years prior to study entry.
4. Inadequate bone marrow, renal, or liver function
5. History or evidence of cardiovascular condition
6. Severe, uncontrolled systemic disease
7. Participants with poorly controlled diabetes or with evidence of clinically
significant diabetic vascular complications.
8. Pregnancy or breast-feeding women.
9. Participants who received any investigational treatment within 4 weeks of study start.
10. Participants with known infection with human immunodeficiency virus (HIV), hepatitis B
virus, or hepatitis C virus.
11. Current chronic daily treatment with corticosteroids (dose >10 mg methylprednisolone
or equivalent [excluding inhaled steroids]).
12. Known hypersensitivity to any of the study drugs or excipients
Maximum Eligible Age: | 70 Years |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Percent Change in Standardized Uptake Value (SUV) on Positron Emission Tomography and Change in Gene Expression With Response |
Time Frame: | From baseline to day 15 |
Safety Issue: | |
Description: | Change in SUVmax from baseline to Day 15 on 18-FDG PET and 68Ga-Affibody HER-2 Imaging PET in correlation with pathological complete response (pCR) in patients treated with preoperative pertuzumab/trastuzumab. |
Secondary Outcome Measures
Measure: | Pathologic complete response in the breast and lymph nodes (ypT0/Tis ypN0) |
Time Frame: | Immediately after the surgery |
Safety Issue: | |
Description: | To determine whether the composite markers can predict pathologic complete response in the breast and lymph nodes in HER-2 positive breast cancer with PH combination with chemotherapy adjuvant therapy. Defined as the absence of any invasive component in the resected breast specimen and all resected lymph nodes following completion of neoadjuvant therapy (ypT0/Tis ypN0). |
Measure: | Invasive disease-free survival (iDFS) (excluding Second Primary Non-Breast Cancer [SPNBC]) |
Time Frame: | Following surgery until Year 5 |
Safety Issue: | |
Description: | To determine the correlation between the composite markers and invasive disease free survival in HER-2 positive breast cancer patients receiving docetaxel, carboplatin, and trastuzumab plus pertuzumab pre-operatively. iDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence; ipsilateral local-regional invasive breast cancer recurrence; distant recurrence; death attributable to any cause; contralateral invasive breast cancer. All SPNBCs and in situ carcinomas (including ductal carcinoma in situ [DCIS] and lobular carcinoma in situ [LCIS]) and non-melanoma skin cancer were excluded as an event. |
Measure: | iDFS (including SPNBC) |
Time Frame: | Following surgery until Year 5 |
Safety Issue: | |
Description: | The iDFS event was defined as the first occurrence of one of the following events: Ipsilateral invasive breast tumor recurrence; ipsilateral local-regional invasive breast cancer recurrence; distant recurrence; death attributable to any cause; contralateral invasive breast cancer; SPNBC (with the exception of non-melanoma skin cancers and in situ carcinoma of any site). |
Measure: | Overall survival (OS) |
Time Frame: | Following surgery until Year 5 |
Safety Issue: | |
Description: | To determine the correlation between the composite markers and overall survival in HER-2 positive breast cancer patients receiving docetaxel, carboplatin, and trastuzumab plus pertuzumab pre-operatively. Percentage of participants who died due to any cause is reported. |
Details
Phase: | N/A |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Fudan University |
Last Updated
May 4, 2020